AzurRx BioPharma Inc. | Ownership
Companies that own AzurRx BioPharma Inc.
Gilder, Gagnon, Howe & Co. LLC
555,196
3.28%
555,196
0.02%
06/30/2018
J. Goldman & Co. LP
542,550
3.21%
452,550
0.13%
06/30/2018
The Vanguard Group, Inc.
400,188
2.37%
286,604
0%
06/30/2018
683 Capital Management LLC
400,000
2.37%
400,000
0.13%
06/30/2018
Parsons Capital Management, Inc.
344,069
2.04%
14,554
0.1%
06/30/2018
Highbridge Capital Management LLC
314,493
1.86%
314,493
0.03%
06/30/2018
Perceptive Advisors LLC
227,272
1.34%
0
0.01%
06/30/2018
Ardsley Advisory Partners
137,197
0.81%
54,697
0.06%
06/30/2018
Opaleye Management, Inc.
130,000
0.77%
130,000
0.09%
06/30/2018
BlackRock Fund Advisors
26,047
0.15%
13,202
0%
06/30/2018
| Address |
760 Parkside Avenue
Brooklyn New York 11226
United States
|
|
Employees
|
- |
| Website |
http://www.azurrx.com |
| Updated |
07/08/2019 |
| AzurRx BioPharma, Inc. is a development stage company, which engages in the research and development of non-systemic biologics for the treatment of patients with gastrointestinal disorders. It offers MS1819 and AZX1101 that are therapeutic proteins products under development. The company was founded on January 30, 2014 and is headquartered in Brooklyn, NY. |
